ClinicalTrials.gg
CompletedNCT00384904Updated Feb 5, 2010

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

A Phase 4 interventional study of Atazanavir/Ritonavir and Atazanavir/Ritonavir + Famotidine in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-02-05.

Sponsored by Bristol-Myers Squibb · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing atazanavir in HIV Infections — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · HIV Infections.

Enrollment
45th of 69
40 · median 55
Started
2006
with 11 others
Phase 4
25 of 73
none open now
Registered
36th of 73
by date
Lead sponsor
25 of 73
Bristol-Myers Squibb

Among the 73 studies testing atazanavir in HIV Infections, this one is the 45th largest by enrollment of the 69 interventional ones that give a count, is one of 12 that started in 2006, is one of 25 in phase 4, and was the 36th registered.

HIV Infections

4,736 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 73 studies testing atazanavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About atazanavir

atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 73 studies testing atazanavir in HIV Infections as a file.
02

Study summary

The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • -infected male and female subjects between the ages of 18 to 65 years old with a 18 to 35 kg/m²
  • Prior to enrollment subjects must be currently receiving Atazanavir/Ritonavir plus at least 2 NRTIs, must have plasma HIV RNA \<400 copies/mL and have >200 cells/mm³
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 4
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • No intervention
    A1

    Drug: Atazanavir/Ritonavir

  • Experimental
    A2

    Drug: Atazanavir/Ritonavir + Famotidine

  • Experimental
    A3

    Drug: Atazanavir/Ritonavir + Famotidine

  • No intervention
    B1

    Drug: Atazanavir/Ritonavir

  • Experimental
    B2

    Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

  • Experimental
    B3

    Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

Interventions

  • DrugAtazanavir/Ritonavir

    Drug page: Atazanavir/ritonavir

    Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.

    Also known as: Reyataz

  • DrugAtazanavir/Ritonavir + Famotidine

    Drug pages: Atazanavir · Ritonavir · Famotidine

    Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.

    Also known as: Reyataz

  • DrugAtazanavir/Ritonavir + Famotidine

    Drug pages: Atazanavir · Ritonavir · Famotidine

    Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.

    Also known as: Reyataz

  • DrugAtazanavir/Ritonavir

    Drug page: Atazanavir/ritonavir

    Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.

    Also known as: Reyataz

  • DrugAtazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

    Drug page: Atazanavir

    Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.

    Also known as: Reyataz

  • DrugAtazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

    Drug page: Atazanavir

    Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.

    Also known as: Reyataz

06

What researchers measure

Primary outcomes

  1. Atazanavir plasma drug concentrations

    Time frame: on days 10, 11, 17, 18, 24 and 25

Secondary outcomes

  1. Ritonavir plasma drug concentrations

    Time frame: on days 10, 11, 17, 18, 24 and 25

  2. Safety measures: Physical examinations

  3. ECGs

    Time frame: entry and discharge

  4. laboratory tests including, liver and renal function

    Time frame: entry, discharge and days 11, 18

  5. CD4 count

    Time frame: discharge

  6. HIV viral load

    Time frame: entry and discharge

07

Study locations

4 sites
  • Garden State Infectious Disease Associates, Pa
    Voorhees, New Jersey 08043, United States
  • Unc Center For Aids Research
    Chapel-Hill, North Carolina 27599, United States
  • Local Institution
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution
    London, Greater London SW10 9TH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2006
First posted
Oct 6, 2006
Start
Dec 2006
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results delay requested
Feb 3, 2010
Last update
Feb 5, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00384904
First posted
Oct 6, 2006
Start date
Dec 2006
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Feb 5, 2010

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atazanavir/ritonavir · Atazanavir · Ritonavir · Famotidine

Start the discussion